Diabetic ketoacidosis (DKA) is the most common acute hyperglycaemic emergency in people with diabetes mellitus. A diagnosis of DKA is confirmed when all of the three criteria are present — ‘D’, either elevated blood glucose levels or a family history of diabetes mellitus; ‘K’, the presence of high urinary or blood ketoacids; and ‘A’, a high anion gap metabolic acidosis. Early diagnosis and management are paramount to improve patient outcomes. The mainstays of treatment include restoration of circulating volume, insulin therapy, electrolyte replacement and treatment of any underlying precipitating event. Without optimal treatment, DKA remains a condition with appreciable, although largely preventable, morbidity and mortality. In this Primer, we discuss the epidemiology, pathogenesis, risk factors and diagnosis of DKA and provide practical recommendations for the management of DKA in adults and children.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cell Death Discovery Open Access 24 August 2022
Pediatric Nephrology Open Access 27 July 2022
Nature Communications Open Access 15 July 2022
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $99.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Umpierrez, G. & Korytkowski, M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat. Rev. Endocrinol. 12, 222–232 (2016).
Umpierrez, G. E., Smiley, D. & Kitabchi, A. E. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann. Intern. Med. 144, 350–357 (2006).
Vellanki, P. & Umpierrez, G. E. Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. Endocr. Pract. 23, 971–978 (2017).
Centers for Disease Control and Prevention. Age-adjusted hospital discharge rates for diabetic ketoacidosis as first-listed diagnosis per 10,000 population, United States, 1988–2009. CDC https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html (2013).
Desai, D., Mehta, D., Mathias, P., Menon, G. & Schubart, U. K. Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis. Diabetes Care 41, 1631–1638 (2018).
Dhatariya, K. K., Skedgel, C. & Fordham, R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabet. Med. 34, 1361–1366 (2017).
Dhatariya, K. K. et al. The cost of treating diabetic ketoacidosis in an adolescent population in the UK: a national survey of hospital resource use. Diabet. Med. 36, 982–987 (2019).
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M. & Fisher, J. N. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32, 1335–1343 (2009). This manuscript describes the current guidelines from the ADA. They are the most used in the world for adults.
Kitabchi, A. E. et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 24, 131–153 (2001).
Benoit, S. R., Zhang, Y., Geiss, L. S., Gregg, E. W. & Albright, A. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality-United States, 2000-2014. Morb. Mortal. Wkly Rep. 67, 362–365 (2018). This paper from the Centers for Disease Control and Prevention illustrates the trends in DKA in the USA over the first 15 years of this century.
Zhong, V. W., Juhaeri, J. & Mayer-Davis, E. J. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care 41, 1870–1877 (2018).
Poovazhagi, V. Risk factors for mortality in children with diabetic ketoacidosis from developing countries. World J. Diabetes 5, 932–938 (2014).
Vellanki, P. & Umpierrez, G. E. Increasing hospitalizations for DKA: A need for prevention programs. Diabetes Care 41, 1839–1841 (2018).
Dabelea, D. et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for Diabetes in Youth Study. Pediatrics 133, e938–e945 (2014).
Neu, A. et al. Ketoacidosis at diabetes onset is still frequent in children and adolescents. A multicenter analysis of 14,664 patients from 106 institutions. Diabetes Care 32, 1647–1648 (2009).
Limenis, E., Shulman, R. & Daneman, D. Is the frequency of ketoacidosis at onset of type 1 diabetes a child health indicator that is related to income inequality? Diabetes Care 35, e5 (2012).
Jefferies, C. A. et al. Preventing diabetic ketoacidosis. Pediatr. Clin. North Am. 62, 857–871 (2015).
Davis, A. K. et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38, 476–481 (2015).
Usher-Smith, J. A., Thompson, M., Ercole, A. & Walter, F. M. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia 55, 2878–2894 (2012).
Pinkney, J. H., Bingley, P. J., Sawtell, P. A., Dunger, D. B. & Gale, E. A. Presentation and progress of childhood diabetes mellitus: a prospective population-based study. Diabetologia 37, 70–74 (1994).
Rewers, A. et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics 121, e1258 (2008). This large dataset shows that, in the USA, 1 in 4 people <20 years of age presented with DKA at the time of diagnosis of diabetes mellitus.
Wolfsdorf, J. I. et al. ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr. Diabetes 19, S155–S177 (2018). This manuscript describes the current guidelines from the International Society for Pediatric and Adolescent Diabetes. They are the most used in the world for children.
Klingensmith, G. J. et al. Presentation of youth with type 2 diabetes in the pediatric diabetes consortium. Pediatr. Diabetes 17, 266–273 (2016).
Mulukutla, S. N., Acevedo-Calado, M., Hampe, C. S., Pietropaolo, M. & Balasubramanyam, A. Autoantibodies to the IA-2 extracellular domain refine the definition of “A+” subtypes of ketosis-prone diabetes. Diabetes Care 41, 2637–2640 (2018).
Farsani, S. F. et al. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open 7, e016587 (2017).
Venkatesh, B. et al. Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New Zealand. Crit. Care 19, 451 (2015).
Henriksen, O. M., Roder, M. E., Prahl, J. B. & Svendsen, O. L. Diabetic ketoacidosis in Denmark. Diabetes Res. Clin. Pract. 76, 51–56 (2007).
Diaz-Valencia, P. A., Bougneres, P. & Valleron, A. J. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 15, 255 (2015).
Li, J. et al. Secondary diabetic ketoacidosis and severe hypoglycaemia in patients with established type 1 diabetes mellitus in China: a multicentre registration study. Diabetes Metab. Res. Rev. 30, 497–504 (2014).
Liu, C. C. et al. Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: Analysis of national claims data, 1997-2005. J. Formos. Med. Assoc. 109, 725–734 (2010).
Lombardo, F., Maggini, M., Gruden, G. & Bruno, G. Temporal trend in hospitalizations for acute diabetic complications: A nationwide study, Italy, 2001-2010. PLoS One 8, e63675 (2013).
Kalscheuer, H. et al. Event rates and risk factors for the development of diabetic ketoacidosis in adult patients with type 1 diabetes: analysis from the DPV registry based on 46,966 patients. Diabetes Care 42, e34–e36 (2019).
Mays, J. A. et al. An evaluation of recurrent diabetic ketoacidosis, fragmentation of care, and mortality across Chicago, Illinois. Diabetes Care 39, 1671–1676 (2016).
Skinner, T. C. Recurrent diabetic ketoacidosis: causes, prevention and management. Horm. Res. 57 (Suppl. 1), 78–80 (2002).
Dhatariya, K. K., Nunney, I., Higgins, K., Sampson, M. J. & Iceton, G. A national survey of the management of diabetic ketoacidosis in the UK in 2014. Diabet. Med. 33, 252–260 (2016). This paper shows that the UK guideline works and that hypoglycaemia and hypokalaemia are common.
Gibb, F. W., Teoh, W. L., Graham, J. & Lockman, K. A. Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia 59, 2082–2087 (2016).
Azevedo, L. C., Choi, H., Simmonds, K., Davidow, J. & Bagshaw, S. M. Incidence and long-term outcomes of critically ill adult patients with moderate-to-severe diabetic ketoacidosis: retrospective matched cohort study. J. Crit. Care 29, 971–977 (2014).
Große, J. et al. Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with human development index (HDI): an updated systematic review, meta-analysis, and meta-regression. Horm. Metab. Res. 50, 209–222 (2018).
Agarwal, A. et al. Prognostic factors in patients hospitalized with diabetic ketoacidosis. Endocrinol. Metab. 31, 424–432 (2016).
Chung, S. T. et al. Predictors of hyperglycaemic crises and their associated mortality in Jamaica. Diabetes Res. Clin. Pract. 73, 184–190 (2006).
Otieno, C. F., Kayima, J. K., Omonge, E. O. & Oyoo, G. O. Diabetic ketoacidosis: risk factors, mechanisms and management strategies in sub-Saharan Africa: a review. East Afr. Med. J. 82, S197–203 (2005).
Randall, L. et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care 34, 1891–1896 (2011).
Torjesen, I. Diabulimia: the world’s most dangerous eating disorder. BMJ 364, l982 (2019).
Lindner, L. M., Rathmann, W. & Rosenbauer, J. Inequalities in glycaemic control, hypoglycaemia and diabetic ketoacidosis according to socio-economic status and area-level deprivation in type 1 diabetes mellitus: a systematic review. Diabet. Med. 35, 12–32 (2018).
Foster, N. C. et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol. Ther. 21, 66–72 (2019).
Shah, V. N. et al. Gender differences in diabetes self-care in adults with type 1 diabetes: findings from the T1D Exchange clinic registry. J. Diabetes Complications 32, 961–965 (2018).
Maahs, D. M. et al. Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care 38, 1876–1882 (2015). This very large dataset looks at the risk factors for developing DKA in children <18 years of age with established T1DM.
Hurtado, C. R. et al. Causes and predictors for 30-day re-admissions in adult patients with diabetic ketoacidosis in the United States: a nationwide analysis, 210-2014. Endocr. Pract. 25, 242–253 (2019).
Del Degan, S., Dube, F., Gagnon, C. & Boulet, G. Risk factors of recurrent diabetic ketoacidosis in adults with type 1 diabetes. Can. J. Diabetes 43, 472–476.e1 (2019).
Bui, H., To, T., Stein, R., Fung, K. & Daneman, D. Is diabetic ketoacidosis at disease onset a result of missed diagnosis? J. Pediatr. 156, 472–477 (2010).
Flood, R. G. & Chiang, V. W. Rate and prediction of infection in children with diabetic ketoacidosis. Am. J. Emerg. Med. 19, 270–273 (2001).
Wolfsdorf, J. I. et al. Diabetic ketoacidosis and hyperglycemic hypersmolar state. Pediatr. Diabetes 15, 154–179 (2014).
Edge, J. A., Nunney, I. & Dhatariya, K. K. Diabetic ketoacidosis in an adolescent and young adult population in the UK in 2014: a national survey comparison of management in paediatric and adult settings. Diabet. Med. 33, 1352–1359 (2016).
Praveen, P. A. et al. Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries. Pediatr. Diabetes https://doi.org/10.1111/pedi.12979 (2020).
Pinhas-Hamiel, O., Hamiel, U. & Levy-Shraga, Y. Eating disorders in adolescents with type 1 diabetes: challenges in diagnosis and treatment. World J. Diabetes 6, 517–526 (2015).
Garrett, C. J., Choudhary, P., Amiel, S. A., Fonagy, P. & Ismail, K. Recurrent diabetic ketoacidosis and a brief history of brittle diabetes research: contemporary and past evidence in diabetic ketoacidosis research including mortality, mental health and prevention. Diabet. Med. 36, 1329–1335 (2019).
Polonsky, W. H. et al. Insulin omission in women with IDDM. Diabetes Care 17, 1178–1185 (1994).
Rydall, A. C., Rodin, G. M., Olmsted, M. P., Devenyi, R. G. & Daneman, D. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N. Engl. J. Med. 336, 1849–1854 (1997).
Price, H. C. & Ismail, K., Joint British Diabetes Societies (JBDS) for Inpatient Care. Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS): guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings. Diabet. Med. 35, 997–1004 (2018).
Healthcare Quality Improvement Partnership & Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit Report 2012-15: Part 2. Hospital admissions and complications. Royal College of Paediatrics and Child Health https://www.rcpch.ac.uk/sites/default/files/2018-03/npda_hospital_admissions_report_part_2_2012-15.pdf (2017)
Erondu, N., Desai, M., Ways, K. & Meininger, G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38, 1680–1686 (2015).
Henry, R. R., Thakkar, P., Tong, C., Polidori, D. & Alba, M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38, 2258–2265 (2015).
Goldenberg, R. M. et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin. Ther. 38, 2654–2664.e1 (2016).
Matthaei, S., Bowering, K., Rohwedder, K., Grohl, A. & Parikh, S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 38, 365–372 (2015).
Fadini, G. P., Bonora, B. M. & Avogaro, A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia 60, 1385–1389 (2017). This paper highlights the relationship between SGLT2 inhibitor use and the risk of developing DKA.
Danne, T. et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42, 1147–1154 (2019).
Garg, S. K., Peters, A. L., Buse, J. B. & Danne, T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol. Ther. 20, 571–575 (2018).
European Medicines Agency. First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. EMA https://www.ema.europa.eu/en/news/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes (2019).
Drugs.com. Pramlintide. Drugs.com https://www.drugs.com/ppa/pramlintide.html (2019).
Kinney, G. L., Akturk, H. K., Taylor, D. D., Foster, N. C. & Shah, V. N. Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: findings from the T1D Exchange Clinic Registry. Diabetes Care 43, 247–249 (2020).
Guenette, M. D., Hahn, M., Cohn, T. A., Teo, C. & Remington, G. J. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology 226, 1–12 (2013).
Ananth, J., Parameswaran, S. & Gunatilake, S. Side effects of atypical antipsychotic drugs. Curr. Pharm. Des. 10, 2219–2229 (2004).
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Akturk, H. K. et al. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet. Med. 36, 1075–1081 (2019).
Wright, J. J. et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care 41, e150–e151 (2018).
Stamatouli, A. M. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67, 1471–1480 (2018).
Akturk, H. K. & Michels, A. W. Adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 1163–1165 (2018).
Foster, D. W. & McGarry, J. D. The metabolic derangements and treatment of diabetic ketoacidosis. N. Engl. J. Med. 309, 159–169 (1983).
Miles, J. M., Rizza, R. A., Haymond, M. W. & Gerich, J. E. Effects of acute insulin deficiency on glucose and ketone body turnover in man: evidence for the primacy of overproduction of glucose and ketone bodies in the genesis of diabetic ketoacidosis. Diabetes 29, 926–930 (1980).
Gerich, J. E., Meyer, C., Woerle, H. J. & Stumvoll, M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24, 382–391 (2001).
Exton, J. H. Gluconeogenesis. Metabolism 21, 945–990 (1972).
Felig, P., Marliss, E., Ohman, J. L. & Cahill, G. F. Plasma amino acid levels in diabetic ketoacidosis. Diabetes 19, 727–728 (1970).
Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K. & Puigserver, P. Insulin regulation of gluconeogenesis. Ann. N. Y. Acad. Sci. 1411, 21–35 (2018).
McGarry, J. D., Woeltje, K. F., Kuwajima, M. & Foster, D. W. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab. Rev. 5, 271–284 (1989).
Foster, D. W. Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J. Clin. Invest. 122, 1958–1959 (2012).
Cook, G. A., King, M. T. & Veech, R. L. Ketogenesis and malonyl coenzyme a content of isolated rat hepatocytes. J. Biol. Chem. 253, 2529–2531 (1978).
Laffel, L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. 15, 412–426 (1999).
Dhatariya, K. Blood ketones: measurement, interpretation, limitations and utility in the management of diabetic ketoacidosis. Rev. Diabet. Stud. 13, 217–225 (2016).
Balasse, E. O. & Fery, F. Ketone body production and disposal: Effects of fasting, diabetes, and exercise. Diabetes Metab. Rev. 5, 247–270 (1989).
Kraut, J. A. & Madias, N. E. Serum anion gap: Its uses and limitations in clinical medicine. Clin. J. Am. Soc. Nephrol. 2, 162–174 (2007).
Witte, D. L., Rodgers, J. L. & Barrett, D. A. The anion gap: its use in quality control. Clin. Chem. 22, 643–646 (1976).
Emmett, M. Anion-gap interpretation: the old and the new. Nat. Clin. Pract. Nephrol. 2, 4–5 (2006).
Kamel, K. S. & Halperin, M. L. Acid-base problems in diabetic ketoacidosis. N. Engl. J. Med. 372, 546–554 (2015).
Palmer, B. F. & Clegg, D. J. Electrolyte and acid-base disturbances in patients with diabetes mellitus. N. Engl. J. Med. 373, 548–559 (2015).
Burnell, J. M., Villamil, M. F., Uyeno, B. T. & Scribner, B. H. The effect in humans of extracellular pH change on the relationship between serum potassium and intracellular potassium. J. Clin. Invest. 35, 935–939 (1956).
Rains, J. L. & Jain, S. K. Oxidative stress, insulin signaling, and diabetes. Free Radic. Biol. Med. 50, 567–575 (2011).
Li, J., Huang, M. & Shen, X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis. J. Diabetes Complications 28, 662–666 (2014).
Shen, T. & Braude, S. Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation. Intern. Med. J. 42, 1347–1350 (2012).
Chaudhuri, A. & Umpierrez, G. E. Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia. J. Diabetes Complications 26, 257–258 (2012).
Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51–60 (2019).
Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest. 127, 1–4 (2017).
Guilherme, A., Henriques, F., Bedard, A. H. & Czech, M. P. Molecular pathways linking adipose innervation to insulin action in obesity and diabetes mellitus. Nat. Rev. Endocrinol. 15, 207–225 (2019).
Vaarala, O. & Yki-Jarvinen, H. Should we treat infection or inflammation to prevent T2DM? Nat. Rev. Endocrinol. 8, 323–325 (2012).
Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27, 813–823 (2004).
Kim, F. et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKb. Arterioscler Thromb. Vasc. Biol. 25, 989–994 (2005).
Stentz, F. B., Umpierrez, G. E., Cuervo, R. & Kitabchi, A. E. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 53, 2079–2086 (2004).
Hoffman, W. H., Stamatovic, S. M. & Andjelkovic, A. V. Inflammatory mediators and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res. 1254, 138–148 (2009).
Glaser, N. et al. Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatr. Diabetes 18, 356–366 (2017).
Omatsu, T. et al. CXCL1/CXCL8 (GROaIL-8) in human diabetic ketoacidosis plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro. Am. J. Physiol. Endocrinol. Metab. 306, E1077–E1084 (2014).
Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39, 1108–1114 (2016).
Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190–1195 (2016).
Ferrannini, E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metabolism 26, 27–38 (2017).
Wanner, C. & Marx, N. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61, 2134–2139 (2018).
Peters, A. L. et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38, 1687–1693 (2015).
Taylor, S. I., Blau, J. E. & Rother, K. I. SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849–2852 (2015).
Palmer, B. F. & Clegg, D. J. Electrolyte disturbances in patients with chronic alcohol-use disorder. N. Engl. J. Med. 377, 1368–1377 (2017).
Umpierrez, G. E. et al. Differences in metabolic and hormonal milieu in diabetic- and alcohol-induced ketoacidosis. J. Crit. Care 15, 52–59 (2000).
Reddi, A. S. in Clinical Evaluation Management (ed. Reddi, A. S.) 85–102 (Springer, 2019).
McGuire, L. C., Cruickshank, A. M. & Munro, P. T. Alcoholic ketoacidosis. Emerg. Med. J. 23, 417–420 (2006).
Cahill, G. F. Fuel metabolism in starvation. Annu. Rev. Nutr. 26, 1–22 (2006).
Cahill, G. F. Starvation in man. N. Engl. J. Med. 282, 668–675 (1970).
Owen, O. E. Ketone bodies as a fuel for the brain during starvation. Biochem. Mol. Biol. Edu. 33, 246–251 (2005).
Wildenhoff, K. E., Ladefoged, K. & Sorensen, N. S. Clinical physiology: the concentration of ketone bodies, free fatty acids, and glycerol in the blood of obese persons after injection of insulin and glucose studies before and during absolute fasting. Scand. J. Clin. Lab. Invest. 35, 129–133 (1975).
Kamel, K. S., Lin, S. H., Cheema-Dhadli, S., Marliss, E. B. & Halperin, M. L. Prolonged total fasting: a feast for the integrative physiologist. Kidney Int. 53, 531–539 (1998).
Xin, Y., Yang, M., Chen, X. J., Tong, Y. J. & Zhang, L. H. Clinical features at the onset of childhood type 1 diabetes mellitus in Shenyang, China. J. Paediatr. Child Health 46, 171–175 (2010).
Umpierrez, G. & Freire, A. X. Abdominal pain in patients with hyperglycemic crises. J. Crit. Care 17, 63–67 (2002).
Umpierrez, G. E., Kelly, J. P., Navarrete, J. E., Casals, M. M. & Kitabchi, A. E. Hyperglycemic crises in urban blacks. Arch. Intern. Med. 157, 669–675 (1997).
Deeter, K. H. et al. Hypertension despite dehydration during severe pediatric diabetic ketoacidosis. Pediatr. Diabetes 12, 295–301 (2011).
Dhatariya, K. K. Defining and characterising diabetic ketoacidosis in adults. Diabetes Res. Clin. Pract. 155, 107797 (2019).
Savage, M. W. et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet. Med. 28, 508–515 (2011). This manuscript describes the current guidelines from the UK and these remain amongst the most used in the world for adults.
Macfarlane, J. & Dhatariya, K. The incidence of euglycemic diabetic ketoacidosis in adults with type 1 diabetes in the United Kingdom before the widespread use of sodium glucose co-transporter 2 inhibitors. Mayo Clin. Proc. 94, 1909–1910 (2019).
Munro, J. F., Campbell, I. W., McCuish, A. C. & Duncan, J. P. Euglycaemic diabetic ketoacidosis. Br. Med. J. 2, 578–580 (1973).
Modi, A., Agrawal, A. & Morgan, F. Euglycemic diabetic ketoacidosis: a review. Curr. Diabetes Rev. 13, 315–321 (2017).
Rosenstock, J. & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015).
Adrogue, H. J., Wilson, H., Boyd, A. E., Suki, W. N. & Eknoyan, G. Plasma acid-base patterns in diabetic ketoacidosis. N. Engl. J. Med. 307, 1603–1610 (1982).
Skellett, S., Mayer, A., Durward, A., Tibby, S. & Murdoch, I. Chasing the base deficit: hyperchloraemic acidosis following 0.9% saline fluid resuscitation. Arch. Dis. Child. 83, 514–516 (2000).
Klocker, A. A., Phelan, H., Twigg, S. M. & Craig, M. E. Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in type 1 diabetes: a systematic review. Diabet. Med. 30, 818–824 (2013).
Wolfsdorf, J. et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr. Diabetes 10, 118–133 (2009).
Sheikh-Ali, M. et al. Can serum β-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care 31, 643–647 (2008).
Stephens, J. M., Sulway, M. J. & Watkins, P. J. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. Diabetes 20, 485–489 (1971).
Pasquel, F. J. et al. Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyperglycemic state: a retrospective, hospital-based cohort study. Diabetes Care 43, 349–357 (2020).
Teasdale, G. & Jennett, B. Assessment of coma and impaired consciousness: a practical scale. Lancet 304, 81–84 (1974).
Laffel, L. Sick-day management in type 1 diabetes. Endocrinol. Metab. Clin. North Am. 29, 707–723 (2000).
Evans, N. R., Richardson, L., Dhatariya, K. K. & Sampson, M. J. Diabetes specialist nurse telemedicine: admissions avoidance, costs and casemix. Eur. Diabetes Nursing 9, 17–21 (2012).
Beran, D., Mirza, Z. & Dong, J. Access to insulin: applying the concept of security of supply to medicines. Bull. World Health Organ. 97, 358–364 (2019).
McLarty, D. G., Kinabo, L. & Swai, A. B. Diabetes in tropical Africa: a prospective study, 1981-7. II. Course and prognosis. Br. Med. J. 300, 1107–1110 (1990).
Shen, X. P., Li, J., Zou, S., Wu, H. J. & Zhang, Y. The relationship between oxidative stress and the levels of serum circulating adhesion molecules in patients with hyperglycemia crises. J. Diabetes Complications 26, 291–295 (2012).
American College of Surgeons Committee on Trauma. Advanced Life Support Course for Physicians (American College of Surgeons, 1993).
Karslioglu French, E., Donihi, A. C. & Korytkowski, M. T. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ 365, l1114 (2019).
Waldhausl, W. et al. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. Diabetes 28, 577–584 (1979).
Dhatariya, K. K. Diabetic ketoacidosis. Br. Med. J. 334, 1284–1285 (2007).
Van Zyl, D. G., Rheeder, P. & Delport, E. Fluid management in diabetic-acidosis - Ringer’s lactate versus normal saline: a randomized controlled trial. QJM 105, 337–343 (2012).
Kamel, K. S., Schreiber, M., Carlotti, A. P. & Halperin, M. L. Approach to the treatment of diabetic ketoacidosis. Am. J. Kidney Dis. 68, 967–972 (2016).
Koves, I. H. et al. The accuracy of clinical assessment of dehydration during diabetic ketoacidosis in childhood. Diabetes Care 27, 2485–2487 (2004).
Sottosanti, M. et al. Dehydration in children with diabetic ketoacidosis: a prospective study. Arch. Dis. Child. 97, 96–100 (2012).
Ugale, J., Mata, A., Meert, K. L. & Sarnaik, A. P. Measured degree of dehydration in children and adolescents with type 1 diabetic ketoacidosis. Pediatr. Crit. Care Med. 13, e103–e107 (2012).
Duck, S. C. & Wyatt, D. T. Factors associated with brain herniation in the treatment of diabetic ketoacidosis. J. Pediatr. 113, 10–14 (1988).
Harris, G. D., Flordalisi, I., Harris, W. L., Mosovich, L. L. & Finberg, L. Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: a retrospective and prospective study. J. Pediatr. 117, 22–31 (1990).
Kuppermann, N. et al. Clinical trial of fluid infusion rates for pediatric diabetic ketoacidosis. N. Engl. J. Med. 378, 2275–2287 (2018). This large trial showed that neither the rate of fluid replacement nor the type of fluid used was associated with adverse neurological outcomes in children <18 years.
Grimberg, A., Cerri, R. W., Satin-Smith, M. & Cohen, P. The “two bag system” for variable intravenous dextrose and fluid administration: benefits in diabetic ketoacidosis management. J. Pediatr. 134, 376–378 (1999). This paper is a retrospective analysis that showed the ‘two-bag’ system was more cost effective and improved quality of care compared with a ‘one-bag’ system in children.
Poirier, M. P., Greer, D. & Satin-Smith, M. A prospective study of the “two-bag system” in diabetic ketoacidosis management. Clin. Pediatr. 43, 809–813 (2004).
So, T. Y. & Grunewalder, E. Evaluation of the two-bag system for fluid management in pediatric patients with diabetic ketoacidosis. J. Pediatr. Pharmacol. Ther. 14, 100–105 (2009).
Oh, G., Anderson, S., Tancredi, D., Kuppermann, N. & Glaser, N. Hyponatremia in pediatric diabetic ketoacidosis: reevaluating the correction factor for hyperglycemia. Arch. Pediatr. Adolesc. Med. 163, 771–772 (2009).
Roscoe, J. M., Halperin, M. L., Rolleston, F. S. & Goldstein, M. B. Hyperglycemia-induced hyponatremia: metabolic considerations in calculation of serum sodium depression. CMAJ 112, 452–453 (1975).
Hillier, T. A., Abbott, R. D. & Barrett, E. J. Hyponatremia: evaluating the correction factor for hyperglycemia. Am. J. Med. 106, 399–403 (1999).
Lindsay, R. & Bolte, R. G. The use of an insulin bolus in low-dose insulin infusion for pediatric diabetic ketoacidosis. Pediatr. Emerg. Care 5, 77–79 (1989).
Kitabchi, A. E., Murphy, M. B., Spencer, J., Matteri, R. & Karas, J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care 31, 2081–2085 (2008).
Nallasamy, K., Jayashree, M., Singhi, S. & Bansal, A. Low-dose vs standard-dose insulin in pediatric diabetic ketoacidosis: a randomized clinical trial. JAMA Pediatr. 168, 999–1005 (2014). This trial showed that in children aged ≤12 years, the rates of glucose decline and resolution of acidosis were the same when comparing insulin given at 0.05 units/kg/hour with 0.1 units/kg/hour.
Puttha, R. et al. Low dose (0.05 units/kg/h) is comparable with standard dose (0.1 units/kg/h) intravenous insulin infusion for the initial treatment of diabetic ketoacidosis in children with type 1 diabetes — an observational study. Pediatr. Diabetes 11, 12–17 (2010).
Al Hanshi, S. & Shann, F. Insulin infused at 0.05 versus 0.1 units/kg/hr in children admitted to intensive care with diabetic ketoacidosis. Pediatr. Crit. Care Med. 12, 137–140 (2011).
Umpierrez, G. E. et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis. Diabetes Care 32, 1164–1169 (2009).
Umpierrez, G. E. et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am. J. Med. 117, 291–296 (2004).
Ersoz, H. O. et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int. J. Clin. Pract. 60, 429–433 (2006).
Karoli, R., Fatima, J., Salman, T., Sandhu, S. & Shankar, R. Managing diabetic ketoacidosis in non-intensive care unit setting: role of insulin analogs. Indian J. Pharmacol. 43, 398–104 (2011).
Umpierrez, G. E. et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 27, 1873–1878 (2004).
Danne, T. et al. ISPAD clinical practice consensus guidelines 2018: insulin treatment in children and adolescents with diabetes. Pediatr. Diabetes 19, 115–135 (2018).
Pozzilli, P. et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab. Res. Rev. 32, 21–39 (2016).
Pala, L., Dicembrini, I. & Mannucci, E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 56, 973–980 (2019).
Blackman, S. M. et al. Insulin pump use in young children in the T1D exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr. Diabetes 15, 564–572 (2014).
Kitabchi, A. E., Ayyagari, V. & Guerra, S. M. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann. Intern. Med. 84, 633–638 (1976).
Sacks, H. S., Shahshahani, M., Kitabchi, A. E., Fisher, J. N. & Young, R. T. Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. Ann. Intern. Med. 90, 36–42 (1979).
Lever, E. & Jaspan, J. B. Sodium bicarbonate therapy in severe diabetic ketoacidosis. Am. J. Med. 75, 263–268 (1983).
Green, S. M. et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. Ann. Emerg. Med. 31, 41–48 (1998).
Latif, K. A., Freire, A. X., Kitabchi, A. E., Umpierrez, G. E. & Qureshi, N. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care 25, 2113–2114 (2002).
Gamba, G., Osequera, J., Casterjon, M. & Gomez-Perez, F. J. Bicarbonate therapy in severe diabetic ketoacidosis. A double blind, randomized, placebo controlled trial. Rev. Invest. Clin. 43, 234–238 (1991).
Glaser, N. et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N. Engl. J. Med. 344, 264–269 (2001). This large dataset suggested that the key risk factors for developing cerebral oedema in children presenting with DKA were a low arterial pCO 2 and high urea at presentation.
Fraley, D. S. & Adler, S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney Int. 12, 354–360 (1977).
Ditzel, J. & Lervang, H. Disturbance of inorganic phosphate metabolism in diabetes mellitus: clinical manifestations of phosphorus-depletion syndrome during recovery from diabetic ketoacidosis. Diabetes Metab. Syndr. Obes. 3, 319–324 (2010).
Shilo, S., Werner, D. & Hershko, C. Acute hemolytic anemia caused by severe hypophosphatemia in diabetic ketoacidosis. Acta Haematol. 73, 55–57 (1985).
Choi, H. S. et al. Respiratory failure in a diabetic ketoacidosis patient with severe hypophosphatemia. Ann. Pediatr. Endocrinol. Metab. 23, 103–106 (2018).
Kutlu, A. O., Kara, C. & Cetinkaya, S. Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatr. Emerg. Care 27, 537–538 (2011).
Winter, R. J., Harris, C. J., Phillips, L. S. & Green, O. C. Diabetic ketoacidosis: induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am. J. Med. 67, 897–900 (1979).
Fisher, J. N. & Kitabchi, A. E. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J. Clin. Endocrinol. Metab. 57, 177–180 (1983).
Wilson, H. K., Keuer, S. P., Lea, A. S., Boyd, A. 3rd & Eknoyan, G. Phosphate therapy in diabetic ketoacidosis. Arch. Intern. Med. 142, 517–520 (1982).
Edge, J. A. et al. The UK case–control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia 49, 2002–2009 (2006).
Lawrence, S. E., Cummings, E. A., Gaboury, I. & Daneman, D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J. Pediatr. 146, 688–692 (2005).
Krane, E. J., Rockoff, M. A., Wallman, J. K. & Wolfsdorf, J. I. Subclinical brain swelling in children during treatment of diabetic ketoacidosis. N. Engl. J. Med. 312, 1147–1151 (1985).
Glaser, N. S. et al. Mechanism of cerebral edema in children with diabetic ketoacidosis. J. Pediatr. 145, 164–171 (2004).
Cameron, F. J. et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 37, 1554–1562 (2014).
Ghetti, S., Lee, J. K., Sims, C. E., DeMaster, D. M. & Glaser, N. S. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J. Pediatr. 156, 109–114 (2010).
Shehata, G. & Eltayeb, A. Cognitive function and event-related potentials in children with type 1 diabetes mellitus. J. Child. Neurol. 25, 469–474 (2010).
Glasgow, A. M. Devastating cerebral edema in diabetic ketoacidosis before therapy. Diabetes Care 14, 77–78 (1991).
Muir, A. B., Quisling, R. G., Yang, M. C. & Rosenbloom, A. L. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care 27, 1541–1546 (2004).
National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management (NG17). NICE https://www.nice.org.uk/guidance/ng17 (2016).
Peasgood, T. et al. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med. Decis. Making 36, 1020–1033 (2016).
Diabetes UK. End of life diabetes care. Diabetes UK https://www.diabetes.org.uk/resources-s3/2018-03/EoL_Guidance_2018_Final.pdf (2018).
Gutierrez, J. A., Bagatell, R., Samson, M. P., Theodorou, A. A. & Berg, R. A. Femoral central venous catheter-associated deep venous thrombosis in children with diabetic ketoacidosis. Crit. Care Med. 31, 80–83 (2003).
Hursh, B. E., Ronsley, R., Islam, N., Mammen, C. & Panagiotopoulos, C. Acute kidney injury in children with type 1 diabetes hospitalized for diabetic ketoacidosis. JAMA Pediatr. 171, e170020 (2017). This paper shows that AKI is seen in almost 65% of children presenting with DKA, with severity of acidosis and circulatory volume depletion being significant risk factors.
Rammaert, B., Lanternier, F., Poiree, S., Kania, R. & Lortholary, O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab. 38, 193–204 (2012).
Ahmed, M., Healy, M. L., O’Shea, D. & Crowley, R. K. Epidural pneumatosis associated with spontaneous pneumomediastinum: a rare complication of diabetic ketoacidosis. BMJ Case Rep. 2016, bcr2016216295 (2016).
Pain, A. R., Pomroy, J. & Benjamin, A. Hamman’s syndrome in diabetic ketoacidosis. Endocrinol. Diabetes Metab. Case Rep. 2017, 17–0135 (2017).
Alsaied, T., Goldstein, S. L., Kaddourah, A. & Poynter, S. E. Thrombocytopenia-associated multi-organ failure caused by diabetic ketoacidosis. Pediatr. Int. 58, 232–234 (2016).
Patra, K. P. & Scott, L. K. Diabetic ketoacidosis preceding thrombocytopenia associated multiple organ failure in a child. JOP 12, 40–43 (2011).
Oschatz, E., Mullner, M., Herkner, H. & Laggner, A. N. Multiple organ failure and prognosis in adult patients with diabetic ketoacidosis. Wien. Klin. Wochenschr. 111, 590–595 (1999).
Baszynska-Wilk, M. et al. Peripheral neuropathy as a complication of diabetic ketoacidosis in a child with newly diagnosed diabetes type 1: a case report. J. Clin. Res. Pediatr. Endocrinol. 10, 289–293 (2018).
Hoeijmakers, J. G., Faber, C. G., Miedema, C. J., Merkies, I. S. & Vles, J. S. Small fiber neuropathy in children: two case reports illustrating the importance of recognition. Pediatrics 138, e20161215 (2016).
Bonfanti, R. et al. Disseminated intravascular coagulation and severe peripheral neuropathy complicating ketoacidosis in a newly diagnosed diabetic child. Acta Diabetol. 31, 173–174 (1994).
Atkin, S. L. et al. Multiple cerebral haematomata and peripheral nerve palsies associated with a case of juvenile diabetic ketoacidosis. Diabet. Med. 12, 267–270 (1995).
Mulder, L., Onur, O., Kleis, L., Borders, H. & Cemeroglu, A. P. Atypical neurologic presentations of new onset type 1 diabetes mellitus in pediatric age group: a report of five unusual cases and review of the literature. J. Ped. Endocrinol. Metab. 27, 749–756 (2014).
Fayfman, M., Pasquel, F. J. & Umpierrez, G. E. Management of hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med. Clin. North Am. 101, 587–606 (2017).
Elding Larsson, H. et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 34, 2347–2352 (2011).
Barker, J. M. et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 27, 1399–1404 (2004).
Vanelli, M. et al. Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices. Diabetes Care 22, 7–9 (1999).
Wagner, D. V., Barry, S. A., Stoeckel, M., Teplitsky, L. & Harris, M. A. NICH at its best for diabetes at its worst: texting teens and their caregivers for better outcomes. J. Diabetes Sci. Technol. 11, 468–475 (2017).
Wong, J. C. et al. Real-time continuous glucose monitoring among participants in the T1D Exchange Clinic registry. Diabetes Care 37, 2702–2709 (2014).
Charleer, S. et al. Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a real-world study. J. Clin. Endocrinol. Metab. 103, 1224–1232 (2018).
Parkin, C. G., Graham, C. & Smolskis, J. Continuous glucose monitoring use in type 1 diabetes: Longitudinal analysis demonstrates meaningful improvements in HbA1c and reductions in health care utilization. J. Diabetes Sci. Technol. 11, 522–528 (2017).
Norgaard, K. A nationwide study of continuous subcutaneous insulin infusion (CSII) in Denmark. Diabet. Med. 20, 307–311 (2003).
Dogan, A. D., Jorgensen, U. L. & Gjessing, H. J. Diabetic ketoacidosis among patients treated with continuous subcutaneous insulin infusion. J. Diabetes Sci. Technol. 11, 631–632 (2017).
Cengiz, E. et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatr. Diabetes 14, 447–454 (2013).
Karges, B. & et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 318, 1358–1366 (2017).
Elliot, J. et al. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabet. Med. 31, 847–853 (2014).
Ilkowitz, J. T., Choi, S., Rinke, M. L., Vandervoot, K. & Heptulla, R. A. Pediatric type 1 diabetes: Reducing admission rates for diabetes ketoacidosis. Qual. Manag. Health Care 25, 231–237 (2016).
World Health Organization. Essential medicines and health products information portal. WHO model formulary, 2008. Based on the 15th model list of essential medicines 2007. WHO https://apps.who.int/iris/bitstream/handle/10665/70656/a95075_eng.pdf;jsessionid=E065A980EC6F9E2FBCEAC09512EC760D?sequence=1 (2009).
Williams, V., Jayashree, M., Nallasamy, K., Dayal, D. & Rawat, A. 0.9% saline versus Plasma-Lyte as initial fluid in children with diabetic ketoacidosis (SPinK trial): a double-blind randomized controlled trial. Crit. Care 24, 1 (2020).
Hsia, E. et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J. Clin. Endocrinol. Metab. 97, 3132–3137 (2012).
Bekiari, E. et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ 361, k1310 (2018).
Karageorgiou, V. et al. Effectiveness of artificial pancreas in the non-adult population: a systematic review and network meta-analysis. Metabolism 90, 20–30 (2019).
Meaden, C. W., Kushner, B. J. & Barnes, S. A rare and lethal complication: cerebral edema in the adult patient with diabetic ketoacidosis. Case Rep. Emerg. Med. 2018, 5043752 (2018).
Nao, J., Zhang, H., Wu, S., Zhang, X. & Zheng, D. Posterior reversible encephalopathy syndrome with spinal cord involvement (PRES-SCI) as a rare complication of severe diabetic ketoacidosis: a case report and review of the literature. Childs Nerv. Syst. 34, 701–705 (2018).
Finn, B. P. et al. Subarachnoid and parenchymal haemorrhages as a complication of severe diabetic ketoacidosis in a preadolescent with new onset type 1 diabetes. Pediatr. Diabetes 19, 1487–1491 (2018).
Weissbach, A. et al. Acute kidney injury in critically ill children admitted to the PICU for diabetic ketoacidosis. A retrospective study. Pediatr. Crit. Care Med. 20, e10–e14 (2019).
Orban, J. C., Maiziere, E. M., Ghaddab, A., Van Obberghen, E. & Ichai, C. Incidence and characteristics of acute kidney injury in severe diabetic ketoacidosis. PLoS One 9, e110925 (2014).
Scordi-Bello, I., Kirsch, D. & Hammers, J. Fatal pulmonary thromboembolism in patients with diabetic ketoacidosis: a seven-case series and review of the literature. Acad. Forensic Pathol. 6, 198–205 (2016).
Wakabayashi, S. et al. Acute multiple arteriovenous thromboses in a patient with diabetic ketoacidosis. Intern. Med. 54, 2025–2028 (2015).
Jorgensen, L. B., Skov, O. & Yderstraede, K. Newly diagnosed type 1 diabetes complicated by ketoacidosis and peripheral thrombosis leading to transfemoral amputation. BMJ Case Rep. 2014, bcr2013202139 (2014).
Cherian, S. V. et al. Diabetic ketoacidosis complicated by generalized venous thrombosis: a case report and review. Blood Coagul. Fibrinolysis 23, 238–240 (2012).
Dixon, A. N., Jude, E. B., Banerjee, A. K. & Bain, S. C. Simultaneous pulmonary and cerebral oedema, and multiple CNS infarctions as complications of diabetic ketoacidosis: a case report. Diabet. Med. 23, 571–573 (2006).
Young, M. C. Simultaneous acute cerebral and pulmonary edema complicating diabetic ketoacidosis. Diabetes Care 18, 1288–1290 (1995).
Quiros, J. et al. Elevated serum amylase and lipase in pediatric diabetic ketoacidosis. Pediatr. Crit. Care Med. 9, 418–422 (2008).
Nair, S., Yadav, D. & Pitchumoni, C. Association of diabetic ketoacidosis and acute pancreatitis: Observations in 100 consecutive episodes of DKA. Am. J. Gastroenterol. 95, 2795–2800 (2000).
Yadav, D., Nair, S., Norkus, E. & Pitchumoni, C. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am. J. Gastroenterol. 95, 3123–3128 (2000).
Finn, B. P., Fraser, B. & O’Connell, S. M. Supraventricular tachycardia as a complication of severe diabetic ketoacidosis in an adolescent with new-onset type 1 diabetes. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-222861 (2018).
Miszczuk, K. et al. Ventricular bigeminy and trigeminy caused by hypophosphataemia during diabetic ketoacidosis treatment: a case report. Ital. J. Pediatr. 45, 42 (2019).
McGreevy, M., Beerman, L. & Arora, G. Ventricular tachycardia in a child with diabetic ketoacidosis without heart disease. Cardiol. Young 26, 206–208 (2016).
Abdulaziz, S., Dabbagh, O., Al Daker, M. O. & Hassan, I. Hypokalaemia and refractory asystole complicating diabetic ketoacidosis, lessons for prevention. BMJ Case Rep. https://doi.org/10.1136/bcr-2012-007312 (2012).
Alanzalon, R. E., Burris, J. R. & Vinocur, J. M. Brugada phenocopy associated with diabetic ketoacidosis in two pediatric patients. J. Electrocardiol. 51, 323–326 (2018).
Haseeb, S. et al. Brugada pattern in diabetic ketoacidosis: a case report and scoping study. Am. J. Med. Case Rep. 6, 173–179 (2018).
Hoffman, W. H. et al. Increased systemic Th17 cytokines are associated with diastolic dysfunction in children and adolescents with diabetic ketoacidosis. PLoS One 8, e71905 (2013).
Atabek, M. E., Pirgon, O., Oran, B., Erkul, I. & Kurtoglu, S. Increased cardiac troponin I concentration in diabetic ketoacidosis. J. Ped. Endocrinol. Metab. 17, 1077–1082 (2004).
Halloum, A. & Al Neyadi, S. Myocardial dysfunction associated with diabetic ketoacidosis in a 5-year-old girl. SAGE Open Med. Case Rep. 7, 2050313X19847797 (2019).
Odubanjo, A. A. et al. Severe myopericarditis in diabetic ketoacidosis - all troponin are not myocardial infarction. Clin. Med. Insights Case Rep. 11, 1179547618763356 (2018).
Casteels, K., Beckers, D., Wouters, C. & Van Geet, C. Rhabdomyolysis in diabetic ketoacidosis. Pediatr. Diabetes 4, 29–31 (2003).
Higa, E. M., Dib, S. A., Martins, J. R., Campos, L. & Homsi, E. Acute renal failure due to rhabdomyolysis in diabetic patients. Renal Failure 19, 289–293 (1997).
Buckingham, B. A., Roe, T. F. & Yoon, J. W. Rhabdomyolysis in diabetic ketoacidosis. JAMA Pediatr. 135, 352–354 (1981).
Wang, L. M., Tsai, S. T., Ho, L. T., Hu, S. C. & Lee, C. H. Rhabdomyolysis in diabetic emergencies. Diabetes Res. Clin. Pract. 26, 209–214 (1994).
DiMeglio, L. A., Chaet, M. S., Quigley, C. A. & Grosfeld, J. L. Massive ischemic intestinal necrosis at the onset of diabetes mellitus with ketoacidosis in a three-year-old girl. J. Ped. Surg. 38, 1537–1539 (2003).
Chan-Cua, S., Jones, K. L., Lynch, F. P. & Freidenberg, G. R. Necrosis of the ileum in a diabetic adolescent. J. Ped. Surg. 27, 1236–1238 (1992).
Pasquel, F. J. & Umpierrez, G. E. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care 37, 3124–3131 (2014).
Munson, E. L. The chemistry of the urine in diabetes mellitus. JAMA 28, 831–836 (1897).
Kussmaul, A., Foulis, D. & Gemmell, S. On a peculiar mode of death in diabetes; on acetonæmia; on the treatment of diabetes by glycerine, and injection of diastase into the blood. GMJ 6, 485–500 (1874).
Stadelmann, E. Ueber die ursachen der pathologischen ammoniakausscheidung beim diabetes mellitus und des coma diabeticum. Archiv fur Experimentelle Pathologie und Pharmakologie 17, 419–444 (1883).
Butler, A. M. Diabetic coma. N. Engl. J. Med. 243, 648–659 (1950).
Page, M. M. et al. Treatment of diabetic coma with continuous low-dose infusion of insulin. Br. Med. J. 2, 687–690 (1974).
Scott, A., Joint British Diabetes Societies (JBDS) for Inpatient Care & jbds Hyperosmolar Hyperglycaemic Guidelines Group. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabet. Med. 32, 714–724 (2015).
Roberts, A., James, J. & Dhatariya, K., Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet. Med. 35, 1011–1017 (2018).
Holt, R. I. G. Association between antipsychotic medication use and diabetes. Curr. Diab. Rep. 19, 96 (2019).
K.K.D. is an employee of the UK National Health Service. N.S.G. has grants from American Diabetes Association (ADA, 1-17-IBS-186) and from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, U34DK123894). E.C. is partly funded by Fondo Nacional de Ciencia y Tecnología (FONDECYT) grant no. 1170895 from the Government of Chile. G.E.U. is partly supported by research grants from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under Award Number UL1TR002378 from the Clinical and Translational Science Award program and an NIH grant U30, P30DK11102, and has received research grant support to Emory University for investigator-initiated studies from Dexcom, Novo Nordisk and Sanofi.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Circulatory volume depletion
A reduction in intravascular and/or extracellular fluid volume, such that there may be an inability to adequately perfuse tissue.
- BMI z-score
Also known as the BMI standard deviation score. The z-score is a measure of a child’s relative weight adjusted for age and gender.
The negative base-10 logarithm of the acid dissociation constant (Ka) of a solution. The lower the pKa, the stronger the acid.
The ability of molecules in the circulation to stabilize the acid–base balance in an attempt to maintain the pH.
- Glomerular filtration rate
An estimate of how much blood passes through the renal glomeruli every minute, which is often calculated from serum creatinine levels, age, sex and body weight.
- Pre-renal failure
The loss of kidney function as a result of poor renal or glomerular perfusion, for example, due to haemorrhage, cardiac failure or hypovolaemia.
A state in which the circulating extracellular fluid has a higher osmotic pressure than the pressure that would be observed in a healthy individual.
About this article
Cite this article
Dhatariya, K.K., Glaser, N.S., Codner, E. et al. Diabetic ketoacidosis. Nat Rev Dis Primers 6, 40 (2020). https://doi.org/10.1038/s41572-020-0165-1
Nature Reviews Disease Primers (2022)
Cell Death Discovery (2022)
Die Diabetologie (2022)
Diabetology International (2022)
Potential Clinical Applications for Continuous Ketone Monitoring in the Hospitalized Patient with Diabetes
Current Diabetes Reports (2022)